Equine herpesvirus type-1 modulates CCL2, CCL3, CCL5, CXCL9, and CXCL10 chemokine expression

Veterinary Immunology and Immunopathology

Volumn 140, Issue 3-4, 2011, Pages 266-274

  Wimer, Christine L ^a   Damiani, Armando ^b   Osterrieder, Nikolaus ^b   Wagner, Bettina ^a  

^a Cornell University ^*  (United States)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Chemokine; EHV 1; Gene expression; Horse; Innate immunity

Indexed keywords

CCL10 CHEMOKINE; CXCL9 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CHEMOTAXIS; DOWN REGULATION; EQUINE HERPES VIRUS; FEMALE; GENE EXPRESSION; HERPES SIMPLEX VIRUS; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; VIRUS INFECTION; VIRUS STRAIN;

ANIMALS; BASE SEQUENCE; CHEMOKINE CCL2; CHEMOKINE CCL3; CHEMOKINE CCL5; CHEMOKINE CXCL10; CHEMOKINE CXCL9; DNA PRIMERS; FEMALE; GENE EXPRESSION; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 1, EQUID; HORSE DISEASES; HORSES; HUMANS; IMMUNITY, INNATE; LEUKOCYTES, MONONUCLEAR; MICE; VIRULENCE;

EQUID HERPESVIRUS 1; EQUIDAE; HERPESVIRIDAE; MURINAE; SIMPLEXVIRUS;

EID: 79952194541     PISSN: 01652427     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vetimm.2011.01.009     Document Type: Article

References (38)

1. Allen G.P. Risk factors for development of neurologic disease after experimental exposure to equine herpesvirus-1 in horses. Am. J. Vet. Res. 2008, 69:1595-1600.
2. APHIS, 2007. Equine Herpesvirus Myeloencephalopathy: A Potentially Emerging Disease. , consulted March 2010. http://www.aphis.usda.gov/animal_health/emergingissues/downloads/ehv1final.pdf.
3. Breathnach C.C., Soboll G., Suresh M., Lunn D.P. Equine herpesvirus-1 infection induces IFN-g production by equine T lymphocyte subsets. Vet. Immunol. Immunopathol. 2005, 103:207-215.
4. Carr D.J.J., Tomanek L. Herpes simplex virus and the chemokines that mediate the inflammation. Curr. Top. Microbiol. Immunol. 2006, 303:47-65.
5. Crowhurst F.A., Dickinson G., Burrows R. An outbreak of paresis in mares and geldings associated with equine herpesvirus-1. Vet. Rec. 1981, 109:527-528.
6. Daly C., Rollins B.J. Monocyte chemoattractant protein-1 (CCL2) in inflammatory disease and adaptive immunity: Therapeutic opportunities and controversies. Microcirculation 2003, 10:247-257.
7. Edington N., Bridges C.G., Patel J.R. Endothelial cell infection and thrombosis in paralysis induced by equid herpesvirus-1: equine stroke. Arch. Virol. 1986, 90:111-124.
8. Finberg R.W., Knipe D.M., Kurt-Jones E.A. Herpes simplex virus and toll-like receptors. Viral Immunol. 2005, 18:457-465.
9. Foote C.E., Love D.N., Gilkerson J.R., Whalley J.M. Detection of EHV-1 and EHV-4 DNA in unweaned Thoroughbred foals from vaccinated mares on a large stud farm. Equine Vet. J. 2004, 36:341-345.
10. Gilkerson J., Love D., Drummer H., Studdert M., Whalley J. Epidemiological studies of equine herpesvirus 1 (EHV-1) in Thoroughbred foals: a review of studies conducted in the Hunter Valley of New South Wales between 1995 and 1997. Vet. Microbiol. 1999, 68:15-25.
11. Goehring L.S., van Winden S.C., van Maanen C., Sloet van Oldruitenborgh-Oosterbaan M.M. Equine herpesvirus type 1-associated myeloencephalopathy in The Netherlands: a four-year retrospective study (1999-2003). J. Vet. Intern. Med. 2006, 20:601-607.
12. Henninger R.W., Reed S.M., Saville W.J., Allen G.A., Hass G.F., Kohn C.W., Sofaly C. Outbreak of neurologic disease caused by equine herpesvirus-1 at a university equestrian center. JAVIM 2007, 21:157-216.
13. Hagglund R., Roizman B. Role of ICP0 in the strategy of conquest of the host cell by Herpes Simplex Virus 1. J. Virol. 2004, 78(5):2169-2178.
14. Kim B., Sarangi P.P., Lee Y., Kaistha S.D., Lee S., Rouse B.T. Depletion of MCP-1 increases development of herpetic stromal keratitis by innate immune modulation. J. Leukoc. Biol. 2006, 80:1405-1415.
15. Kohn C.W., Reed S.M., Sofaly C.D., Henninger R.W., Saville W.J., Allen G.P., Premanadan C. Transmission of EHV -1 in horses with EHV -1 myeloencephalopathy: implications for biosecurity and review. Clin. Tech. Equine Pract. 2006, 5:60-66.
16. Kydd J., Smith K.C., Hannant D., Livesay G.J., Mumford J.A. Distribution of equid herpesvirus-1 (EHV-1) in the respiratory tract associated lymphoid tissue: Implications for cellular immunity. Equine Vet. J. 1994, 26:470-473.
17. Kydd J.H., Townsend H.G., Hannant D. The equine immune response to equine herpesvirus-1: the virus and its vaccines. Vet. Immunol. Immunopathol. 2006, 111:15-30.
18. Lunn D.P., Davis-Poynter N., Flaminio M.J., Horohov D.W., Osterrieder K., Pusterla N., Townsend H.G. Equine herpesvirus-1 consensus statement. J. Vet. Intern. Med. 2009, 23:450-461.
19. Nugent J., Birch-Machin I., Smith K.C., Mumford J.A., Swann Z., Newton J.R., Bowden R.J., Allen G.P., Davis-Poynter N. Analysis of equid herpesvirus 1 strain variation reveals a point mutation of the DNA polymerase strongly associated with neuropathogenic versus nonneuropathogenic disease outbreaks. J. Virol. 2006, 89:4047-4060.
20. Osterrieder N., Van de Walle G.R. Pathogenic potential of equine alphaherpesviruses: the importance of the mononuclear cell compartment in disease outcome. Vet. Microbiol. 2010, 143:21-28.
21. Paillot R., Ellis S.A., Daly J.M., Audonnet J.C., Minke J.M., Davis-Poynter N., Hannant D., Kydd J. Characterisation of CTL and IFN-γ synthesis in ponies following vaccination with a NYVAC-based construct coding for EHV-1 immediate early gene, followed by challenge infection. Vaccine 2006, 24:1490-1500.
22. Paillot R., Daly J.M., Luce1 R., Montesso F., Davis-Poynter N., Hannant D., Kydd J.H. Frequency and phenotype of EHV-1 specific IFN-gama synthesising lymphocytes in ponies: the effects of age, pregnancy and infection. Dev. Comp. Immunol. 2007, 31:202-214.
23. Patel J.R., Heldens J. Equine herpesviruses 1 (EHV-1) and 4 (EHV-4)-epidemiology, disease and immunoprophylaxis: a brief review. Vet. J. 2005, 170:14-23.
24. Perkins G.A., Goodman L.B., Tsujimura K., Van de Walle G.R., Kim S.G., Dubovi E.J., Osterrieder N. Investigation of the prevalence of neurologic equine herpes virus type 1 (EHV-1) in a 23-year retrospective analysis (1984-2007). Vet. Microbiol. 2009, 139:375-378.
25. Radbruch A., Isaacs J. Viewpoints on animal models of human disease. Eur. J. Immunol. 2009, 39:1991-1993.
26. Rebenko-Molla N., Liua L., Cardonaa A., Ransohoff R. Chemokines, mononuclear cells, and the nervous system: heaven (or hell) is in the details. Curr. Opin. Immunol. 2006, 18(6):683-689.
27. Ririe K.M., Rasmussen R.P., Wittwer C.T. Product differentiation by analysis of DNA melting curves during the polymerase chain reaction. Anal. Biochem. 1997, 245:154-160.
28. Slater J.D., Borchers K., Thackray A.M., Field H.J. The trigeminal ganglion is a location for equine herpesvirus 1 latency and reactivation in the horse. J. Gen. Virol. 1994, 75:2007-2016.
29. Smith K.C., Borchers K. A study of the pathogenesis of equid herpesvirus-1 (EHV-1) abortion by DNA in-situ hybridization. J. Comp. Pathol. 2001, 125:304-310.
30. Smith P.M., Zhang Y., Grafton W.D., Jenning S.R., O'Callaghan D.J. Severe murine lung immunopathology elicited by the pathogenic equine herpesvirus 1 strain RacL11 correlates with the early production of macrophage inflammatory proteins 1alpha, 1beta, and 2 and tumor necrosis factor alpha. J. Virol. 2000, 74:10034-10040.
31. Smith P.M., Kahan S.M., Rorex C.B., von Einem J., Osterrieder N., O'Callaghan D.J. Expression of the full-length form of gp2 of equine herpesvirus 1 (EHV-1) completely restores respiratory virulence to the attenuated EHV-1 strain KyA in CBA mice. J. Virol. 2005, 79:5105-5115.
32. Van de Walle G.R., Sakamoto K., Osterrieder N. CCL3 and viral chemokine-binding protein gG modulate pulmonary inflammation and virus replication during equine herpesvirus type 1 (EHV-1) infection. J. Virol. 2008, 82:1714-1722.
33. Van De Walle G.R., Jarosinski K.W., Osterrieder N. Alphaherpesviruses and chemokines: Pas de deux not yet brought to perfection. J. Virol. 2008, 82:6090-6097.
34. Van de Walle G.R., Maya M.A., Petersa S.T., Metzgera S.M., Rosasa C.T., Osterrieder N. A vectored equine herpesvirus type 1 (EHV-1) vaccine elicits protective immune responses against EHV-1 and H3N8 equine influenza virus. Vaccine 2010, 28:1048-1055.
35. Wagner B., Freer H. Development of a bead-based multiplex assay for simultaneous quantification of cytokines in horses. Vet. Immunol. Immunopathol. 2009, 127:242-248.
36. Wuest T., Farber J., Luster A., Carr D.J. CD4+ T cell migration into the cornea is reduced in CXCL9 deficient but not CXCL10 defidient mice following herpes simplex virus type 1 infection. Cell. Immunol. 2006, 234:83-89.
37. Wuest T., Carr D.J. The role of chemokines during herpes simplex virus-1 infection. Front. Biosci. 2008, 13:4862-4872.
38. Zhang Y.W., Davis E.G., Jianfa B. Determination of internal control for gene expression studies in equine tissues and cell culture using quantitative RT-PCR. Vet. Immunol. Immunopathol. 2009, 130:114-119.